Indivisible Partners Buys Shares of 12,823 Merck & Co., Inc. $MRK

Indivisible Partners bought a new stake in Merck & Co., Inc. (NYSE:MRK) during the fourth quarter, Holdings Channel.com reports. The institutional investor bought 12,823 shares of the company’s stock, valued at approximately $1,350,000.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Merck & Co., Inc. by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock worth $26,770,014,000 after purchasing an additional 2,185,853 shares in the last quarter. DLD Asset Management LP lifted its position in shares of Merck & Co., Inc. by 30.1% during the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after purchasing an additional 11,000,000 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Merck & Co., Inc. by 5.9% during the third quarter. Legal & General Group Plc now owns 20,659,157 shares of the company’s stock worth $1,733,923,000 after purchasing an additional 1,156,112 shares in the last quarter. Invesco Ltd. lifted its position in shares of Merck & Co., Inc. by 16.6% during the third quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock worth $1,665,585,000 after purchasing an additional 2,821,766 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its position in shares of Merck & Co., Inc. by 20.7% during the third quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock worth $1,336,877,000 after purchasing an additional 2,735,459 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on MRK shares. Weiss Ratings reissued a “hold (c+)” rating on shares of Merck & Co., Inc. in a research report on Friday. Royal Bank Of Canada reissued an “outperform” rating and set a $142.00 price target on shares of Merck & Co., Inc. in a research report on Monday, March 30th. JPMorgan Chase & Co. increased their price target on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research report on Monday, April 6th. Citigroup increased their price target on shares of Merck & Co., Inc. from $120.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, March 20th. Finally, Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $128.18.

Insider Activity

In other Merck & Co., Inc. news, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $121.87, for a total value of $1,828,050.00. Following the transaction, the insider directly owned 21,197 shares in the company, valued at $2,583,278.39. This represents a 41.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP David Michael Williams sold 5,000 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $121.91, for a total transaction of $609,550.00. Following the completion of the transaction, the executive vice president owned 30,838 shares in the company, valued at $3,759,460.58. This represents a 13.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 209,258 shares of company stock valued at $25,101,593. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Stock Up 0.1%

MRK stock opened at $113.21 on Wednesday. The company’s 50 day moving average price is $117.51 and its 200 day moving average price is $107.91. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14. The firm has a market capitalization of $279.62 billion, a price-to-earnings ratio of 31.89, a PEG ratio of 2.24 and a beta of 0.18.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 26.84%. The firm had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the prior year, the firm earned $2.22 earnings per share. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 5.15 EPS for the current fiscal year.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck completed the acquisition of Terns Pharmaceuticals, adding clinical-stage oncology assets to its pipeline—a near-term catalyst for growth and synergy expectations. Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
• Positive Sentiment: Analysts and commentators point to continued KEYTRUDA-driven revenue and a strong pipeline; Merck delivered its fourth straight beat, supporting the view the stock may be undervalued on a longer-term basis. Merck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term Headwinds
• Positive Sentiment: High-profile media support: Jim Cramer highlighted Merck’s solid quarter and said the stock is “starting to come back,” which can boost retail demand and sentiment. Jim Cramer on Merck & Co.: “The Stock’s Starting to Come Back”
• Neutral Sentiment: Institutional commentary: recent investor letters and analyst write-ups (e.g., Baron Capital coverage) review Merck as a core healthcare holding—useful background but not an immediate catalyst. What Makes Merck & Co. (MRK) an Investment Bet?
• Neutral Sentiment: Sector news: Pfizer beat Q1 estimates but faces a looming patent cliff; competitive results and sector rotation can influence pharma multiples and investor attention, creating mixed pressure across large peers including Merck. Pfizer Beats Sales Estimates As $17 Billion Patent Cliff Looms
• Negative Sentiment: Technical/short-term risk: chart analysts warn a double-top breakdown and moving-average pressures that could produce a deeper correction, which may cap near-term upside despite fundamental positives. Merck (MRK) Price Forecast: Double Top Signals Deeper Correction Risk

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.